证券代码：688076 证券简称：诺泰生物 公告编号：2023-065 江苏诺泰澳赛诺生物制药股份有限公司 2023年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募 集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》和《上 海证券交易所科创板上市公司自律监管规则适用指引第1号——规范运作》等 相关法律法规及公司相关制度的规定及要求，江苏诺泰澳赛诺生物制药股份有 限公司（以下简称"公司"或"诺泰生物"）董事会将公司2023年半年度募集 资金存放与实际使用情况专项说明如下： （一）实际募集资金金额、资金到账时间 一、募集资金基本情况 注 2：2023 年 5 月 22 日，经第三届董事会第十一次会议、第三届监事会第八次会议审 议，通过了《关于首次公开发行股票部分募集资金投资项目结项并将节余募集资金用于新建 项目及永久补充流动资金的议案》，同意公司将首次公开发行股票募集资金投资项目"多肽 类药物及高端制剂研发 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2023-064 江苏诺泰澳赛诺生物制药股份有限公司 第三届监事会第十次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"） 第三届监事会 第十次会议于2023年8月28日上午11:30以通讯会议方式召开，会议通知于2023 年 8 月 18 日以电子邮件方式送达全体监事。本次会议应出席监事 3 人，实际出 席监事 3 人，会议由监事会主席刘标先生主持。会议的召开程序符合有关法律法 规、规范性文件和《公司章程》的规定，会议合法、有效。 二、审议通过了《关于公司<2023 年半年度募集资金存放与实际使用情况的 专项报告>的议案》 议案内容：详见《江苏诺泰澳赛诺生物制药股份有限公司 2023 年半年度募 集资金存放与实际使用情况的专项报告》（公告编号：2023-065）。 经审议，监事会认为：公司严格按照《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2023-066 江苏诺泰澳赛诺生物制药股份有限公司 1.基本信息 中天运会计师事务所（特殊普通合伙）（以下简称"中天运"）始建于 1994 年 3 月，2013 年 12 月完成转制，取得《北京市财政局关于同意设立中天运会计 师事务所（特殊普通合伙）的批复》（京财会许可[2013]0079 号）。组织形式： 特殊普通合伙。注册地址：北京市西城区车公庄大街 9 号院 1 号楼 1 门 701-704。 首席合伙人：刘红卫先生。 2022 年末，合伙人 68 人，注册会计师 415 人，签署过证券服务业务审计报 告的注册会计师 193 人。 最近一年（2022 年度）经审计的收入总额为 68,273.53 万元、审计业务收 入为 45,735.76 万元，证券业务收入为 13,450.33 万元。 2022 年度上市公司审计客户家数 57 家，涉及的主要行业包括制造业，水利、 环境和公共设施管理业，批发和零售业，交通运输、仓储和邮政业，文化、体育 和娱乐业，电力、热力、燃气及水生产和供应业，信息传输、软件和信息技术服 关于续聘会计师事务所的公告 本公司董事会 ...

江苏诺泰澳赛诺生物制药股份有限公司独立董事 关于公司续聘会计师事务所的事前认可意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易所 科创板股票上市规则》、《上市公司独立董事规则》等法律、法规及规范性文件及《公 司章程》的相关规定，我们作为江苏诺泰澳赛诺生物制药股份有限公司（以下简称 "公司"）的独立董事，本着勤勉尽责的态度，依据客观公正的原则，对公司续聘会 计师事务所进行了认真的审查，现发表如下事前认可意见： 公司 2022 年度聘请了中天运会计师事务所（特殊普通合伙）担任本公司财务审 计机构，在对公司各专项审计和财务报表审计过程中，该所能够按照国家有关规定 及注册会计师职业规范的要求开展审计工作，独立、客观的发表审计意见，建议继 续聘任中天运会计师事务所（特殊普通合伙）担任本公司 2023 年度审计机构及内部 控制审计机构，同意公司将该议案提交第三届董事会第十三次会议审议。 江苏诺泰澳赛诺生物制药股份有限公司 独立董事：徐强国、高集馥、曲峰、胡文言 2023 年 8 月 21 日 ...

经核查，我们认为：中天运会计师事务所（特殊普通合伙）具备从事证券、 期货相关业务的资格，具有丰富的上市公司审计经验和素质优良的执业队伍，可 以满足公司 2023 年度审计业务的要求。本次续聘会计师事务所事项已经公司全 体独立董事事前认可、董事会审计委员会审议通过，履行了必要的决策程序，符 合《公司法》、《国有企业、上市公司选聘会计师事务所管理办法》和《公司章程》 等相关规定，不存在损害公司和股东利益的行为。因此，我们一致同意聘任中天 运会计师事务所（特殊普通合伙）为公司 2023 年度会计师事务所，聘期一年， 并提交公司股东大会审议。 江苏诺泰澳赛诺生物制药股份有限公司 独立董事：徐强国、高集馥、曲峰、胡文言 2023 年 8 月 28 日 一、《关于公司<2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》的独立意见 经核查，我们认为：报告期内，公司严格按照《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律法规和公司《募集资金管理办法》等文件的规定管理和使用募集资金，并 及时进行信息披露，不存在募集资金存放和使用重大违法违规的情形。 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2023-063 江苏诺泰澳赛诺生物制药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 2023 年 7 月 25 日，江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺 泰生物"或"公司"）于上海证券交易网站披露了《关于股东存续分立完成的公 告》（公告编号：2023-060）, 公司股东建德市五星生物科技有限公司（以下简 称"五星生物"）完成存续分立，五星生物所持 10,314,700 股公司股份已全部过 户给分立公司建德市星联企业管理有限公司（以下简称"星联管理"）。 截至本公告披露之日，公司股东星联管理持有公司股份 10,314,700 股，占 公司总股本的 4.84%；建德市上将企业管理有限公司（以下简称"上将管理"）持 有公司股份 8,809,794 股，占公司总股本的 4.13%；股东潘婕持有公司股份 594,141 股，占公司总股本的 0.28%。星联管理、上将管理、潘婕作为 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2023-042 江苏诺泰澳赛诺生物制药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 06 月 01 日(星期四) 下午 14:00-15:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 25 日(星期四) 至 05 月 31 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinopep.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者 ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.00 per 10 shares to all shareholders, totaling RMB 42,636,760.00 based on a total share capital of 213,183,800 shares as of March 31, 2023[5]. - The company has a total share capital of 213,183,800 shares as of March 31, 2023, which is the basis for the proposed dividend distribution[5]. - The company has not engaged in any capital increase through bonus shares or conversion of capital reserves into share capital for the 2022 fiscal year[5]. Operational Risks and Governance - The company has not reported any profits since its listing and continues to face operational risks as detailed in the report[18]. - The company has implemented a series of governance improvements, including revisions to various internal management systems to enhance operational compliance and protect shareholder rights[26]. - The company has outlined various risk factors that may impact its future operations, emphasizing the uncertainties in its forward-looking statements[11]. Investor Relations and Communication - The company has established effective communication channels with investors, including email, on-site research, and official social media platforms, to disseminate strategic and operational updates[26]. - The company has established a structured approach to investor relations management, with designated personnel responsible for coordinating communication and addressing investor inquiries[30]. - The company commits to maintaining strict compliance with information disclosure obligations to ensure transparency and accuracy in reporting[26]. Share Transfer and Lock-up Regulations - Shareholders are restricted from transferring shares for one year from the date of listing on the Shanghai Stock Exchange[40]. - The company commits to not transferring or managing its shares directly or indirectly for 12 months post-IPO and for 6 months after any executive's departure[39]. - Any shareholder's transfer of pre-IPO shares is limited to 25% of their total pre-IPO shares each year for four years post-lockup expiration[39]. - If the closing price falls below the issue price for 20 consecutive trading days, the lock-up period will be extended by 6 months[42]. - The lock-up period for shareholders will automatically extend if the stock price remains below the issue price at the end of the 6-month period post-IPO[43]. - The company emphasizes strict adherence to share lock-up and reduction commitments to ensure compliance with regulatory requirements[45]. Stock Price Stabilization Measures - The company commits to stabilize its stock price if it falls below the audited net asset value per share for 20 consecutive trading days within three years post-IPO[46]. - Stock repurchase will be the first option for stabilizing the stock price, with a limit of 10% of total shares and funding not exceeding 20% of the previous year's net profit attributable to shareholders[46]. - If the stock repurchase plan is not approved or cannot be implemented, the actual controller and major shareholders will increase their holdings as the second option[46]. - The company must hold a board meeting within 10 days to decide on the stock repurchase if the stabilization conditions are met[46]. - The stock repurchase must be completed within three months after the shareholders' meeting approval[46]. - The company will only be obligated to initiate stock price stabilization measures once per fiscal year[46]. - If the stock price exceeds the audited net asset value for three consecutive trading days during the stabilization period, the obligation is considered fulfilled for that year[46]. - The company will ensure that any stock repurchase does not lead to non-compliance with legal listing requirements[46]. - The stabilization measures will be suspended if the stock price rises above the audited net asset value before the implementation of the plan[46]. Financial Performance and Investments - The total amount of funds raised for the Hangzhou Aoxin Pharmaceutical Intermediate Construction Project is CNY 150 million, with a cumulative investment of CNY 119.62 million, achieving a progress rate of 79.75%[110]. - The Peptide Raw Material Drug Product Technical Transformation Project has a total fundraising commitment of CNY 250 million, with a cumulative investment of CNY 18.37 million, resulting in a progress rate of 7.35%[111]. - The total amount of funds raised for the Peptide Drug and High-end Preparation R&D Center Project is CNY 100 million, with a cumulative investment of CNY 32.42 million, achieving a progress rate of 32.42%[111]. - The company has achieved benefits of CNY 47.22 million from the investment projects[110]. - The company has a remaining balance of CNY 31.25 million from the fundraising projects, with reasons for the surplus detailed in the report[110]. Environmental Compliance - The company has implemented measures to ensure that waste gas and wastewater meet environmental standards before discharge, with zero emissions for solid waste[160]. - The Lianyungang production base has received multiple environmental approvals from regulatory authorities, ensuring compliance with environmental regulations[160]. - The company’s wastewater treatment facilities have been approved, with the latest permit renewal for the JianDe production base on December 2, 2022[160]. - The company has established a comprehensive environmental management system, including noise reduction measures and the use of green plants for sound absorption[162]. - The company is focused on maintaining zero discharge of solid waste, reflecting its commitment to environmental sustainability[160]. Shareholder Structure and Changes - The total number of common shareholders as of the end of the reporting period is 10,938, an increase from 10,609 at the end of the previous month[151]. - The top ten shareholders hold a total of 66,000,000 shares, representing 30.94% of the total shares[151]. - The largest shareholder, Lianyungang Nuotai Investment Management Partnership, holds 20,000,000 shares, accounting for 9.38% of the total shares[151]. - The company has not reported any significant changes in shareholder structure or asset and liability structure during the reporting period[125]. - The company has not reported any changes in the number of shares held by the top shareholders during the reporting period[155]. Financial Position - Total assets increased to ¥2,522,299,186.67, up from ¥2,126,905,940.12, representing a growth of approximately 18.6% year-over-year[198]. - Non-current assets totaled ¥1,469,829,602.50, compared to ¥1,022,805,046.06, marking a significant increase of about 44%[198]. - Short-term borrowings rose to ¥318,725,147.08 from ¥77,274,866.38, indicating a substantial increase of approximately 312%[198]. - Current liabilities totaled ¥551,323,149.93, up from ¥275,395,497.17, reflecting an increase of around 100%[198]. - The company reported a significant increase in accounts payable, rising to ¥110,735,822.36 from ¥76,919,527.44, which is an increase of about 44%[198].

Financial Performance - In Q1 2023, the company reported a net profit of ¥18,885,415.84, an increase from ¥14,993,326.89 in Q1 2022, representing a growth of approximately 25.6%[12] - Basic earnings per share for Q1 2023 was reported at ¥0.10, up from ¥0.08 in Q1 2022, indicating a growth of 25%[12] - The company’s operating profit for the quarter was ¥23,528,055.19, compared to ¥14,930,312.73 in the same period last year, reflecting a significant increase of about 57.5%[12] - The net profit attributable to shareholders of the listed company for Q1 2023 was RMB 21,012,921.56, reflecting a 30.56% year-on-year growth[30] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 23,382,586.67, which is an increase of 84.35% year-on-year[30] - The net profit after deducting non-recurring gains and losses surged by 84.35% due to increased sales revenue[42] Assets and Liabilities - The total assets as of March 31, 2023, amounted to ¥2,592,700,235.07, compared to ¥2,522,299,186.67 at the end of 2022, indicating an increase of about 2.8%[10] - The total liabilities rose to ¥648,695,474.24 from ¥597,412,479.77, marking an increase of about 8.6%[10] - The total equity attributable to shareholders increased to ¥1,931,471,658.69 from ¥1,910,226,099.04, representing a growth of approximately 1.1%[10] - The total non-current assets reached RMB 1,502,113,796.17, compared to RMB 1,469,829,602.50 in the previous year[36] - The total liabilities for the company were RMB 604,120,687.19, an increase from RMB 551,323,149.93 in the previous year[36] Cash Flow - The company's cash and cash equivalents increased to ¥478,034,709.32 from ¥399,964,705.79 year-over-year, reflecting a growth of approximately 19.5%[9] - The net cash flow from operating activities for Q1 2023 was RMB 144,720,177.89, showing a significant increase of 9,897.52% compared to the previous year[30] - Cash flow from operating activities amounted to CNY 144,720,177.89, significantly up from CNY 1,447,560.62 in the previous period[50] - Net cash inflow from operating activities was CNY 308,976,823.93, compared to CNY 144,960,960.65 in the previous year[50] - The net increase in cash and cash equivalents was $94,551,033.29, contrasting with a decrease of $37,593,550.63 in the previous year[61] Revenue and Expenses - The company's total operating revenue for Q1 2023 was RMB 208,058,681.69, representing a 54.98% increase compared to the same period last year[30] - Operating revenue for the period was CNY 208,058,681.69, a 54.98% increase year-on-year[48] - Research and development expenses totaled CNY 20,884,102.29, representing a 59.59% increase[42] - Research and development expenses accounted for 10.04% of operating revenue, up 0.29 percentage points[41] Shareholder Information - The company has a total of 10,609 shareholders at the end of the reporting period[32] - The weighted average return on equity rose to 1.09%, an increase of 0.21 percentage points[41] Other Financial Activities - The company reported a loss of RMB 5,502,004.42 from the disposal of a waste warehouse during the reporting period[30] - The company received government subsidies amounting to RMB 2,731,880.44, which are closely related to its normal business operations[30] - The company has no reported financing or margin trading activities among its top shareholders[7] - There were no mergers or acquisitions reported during the period, with no net profit from merged entities[13] - Cash inflow from investment activities totaled $106,461,541.49, down from $212,512,573.97 year-over-year[61] - Cash outflow for investment activities was $252,391,749.91, compared to $315,912,070.61 in the previous period[61] - Net cash flow from investment activities was -$145,930,208.42, worsening from -$103,399,496.64 year-over-year[61] - Cash inflow from financing activities increased to $155,000,000.00, up from $82,700,000.00 in the previous period[61] - Cash outflow for financing activities was $59,236,521.22, compared to $18,190,587.09 last year[61] - Net cash flow from financing activities improved to $95,763,478.78, compared to $64,509,412.91 in the previous period[61]

Financial Performance - Revenue for Q3 2022 was ¥113,938,273.65, a decrease of 19.12% compared to the same period last year[8] - Net profit attributable to shareholders for Q3 2022 was ¥18,361,297.20, down 16.02% year-over-year[8] - Net profit excluding non-recurring gains and losses for Q3 2022 was ¥578,020.36, a significant decline of 96.85% compared to the same period last year[8] - Total operating revenue for the first three quarters of 2022 was ¥382,238,680.01, a decrease of 15% compared to ¥449,877,162.41 in the same period of 2021[32] - Net profit for the third quarter of 2022 was ¥48,653,233.84, down 30% from ¥69,525,337.97 in the third quarter of 2021[38] - Earnings per share for the third quarter of 2022 were ¥0.25, compared to ¥0.40 in the same quarter of 2021[40] Research and Development - R&D investment for Q3 2022 totaled ¥20,523,354.60, an increase of 49.04% year-over-year, representing 18.01% of revenue[12] - Research and development expenses for the third quarter of 2022 were ¥49,547,134.58, an increase from ¥44,422,127.37 in the previous year[35] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥2,376,710,654.67, an increase of 11.74% from the end of the previous year[12] - The company's total assets amounted to approximately ¥2.38 billion, an increase from ¥2.13 billion at the end of 2021, reflecting a growth of about 11.7%[30] - The company's total liabilities increased to ¥526,122,650.75 in 2022 from ¥318,137,446.34 in 2021[32] - Total current liabilities rose to approximately ¥483.28 million, up from ¥275.40 million, reflecting an increase of about 75.4% year-over-year[30] - The company's non-current assets totaled approximately ¥1.36 billion, an increase from ¥1.02 billion, indicating a growth of about 33.1%[30] Cash Flow - Cash flow from operating activities for the year-to-date was negative at -¥15,425,321.93, a decline of 111.70% compared to the previous year[12] - The net cash flow from operating activities was -$15,425,321.93, a significant decrease compared to $131,827,280.03 in the previous period[42] - Cash inflow from operating activities for the first three quarters of 2022 was ¥409,786,781.52, down from ¥554,516,533.82 in the same period of 2021[41] - The cash outflow for operating activities was $425,212,103.45, slightly higher than $422,689,253.79 in the previous period[42] Investments and Financing - The company reported a significant increase in investment income to ¥19,813,526.18 in the third quarter of 2022, compared to ¥1,790,339.17 in the same quarter of 2021[35] - Cash inflow from investment activities totaled $633,880,182.43, slightly down from $638,790,339.17 year-over-year[42] - The net cash flow from investment activities was -$349,190,220.68, worsening from -$202,083,694.94 in the prior period[42] - Cash inflow from financing activities was $372,140,000.00, a decrease from $884,930,398.14 in the previous year[42] - The net cash flow from financing activities was $218,839,953.16, down from $521,003,577.78 year-over-year[42] Other Notable Points - The company reported an increase in management and sales expenses, contributing to the decline in net profit[17] - The company's cash and cash equivalents decreased to approximately ¥428.81 million from ¥591.88 million, representing a decline of about 27.5% year-over-year[27] - Inventory levels increased significantly to approximately ¥330.17 million, up from ¥250.82 million, indicating a rise of approximately 31.7% compared to the previous year[27] - The company's short-term borrowings surged to approximately ¥298.36 million, compared to ¥77.27 million at the end of 2021, marking an increase of about 286.5%[30] - The company has no significant updates regarding new products or technologies in the current report period[24] - There are no notable mergers or acquisitions reported during the current period[24] - The company has not provided specific future guidance or outlook in the current report[24]